The Roll Back Malaria (RBM) Partnership to End Malaria has Tuesday issued an urgent appeal to leaders and health policymakers across Africa to better protect millions of pregnant women and their newborn children from the devastating consequences caused by malaria in pregnancy.
Malaria strikes hardest against pregnant women and children in sub-Saharan Africa, who are now at even higher risk from the disease due to the COVID-19 pandemic.
An estimated 11 million pregnant women in sub-Saharan Africa were infected with malaria in 2018 (29% of pregnancies), resulting in nearly 900,000 children born with low birth weight, a leading cause of child mortality.
Even when death is averted, low birthweight has adverse consequences on children’s growth and cognitive development. Each year, maternal malaria is also responsible for 20% of stillbirths in sub-Saharan Africa.
Despite progress over recent years, in 2018, more than two-thirds of eligible women across 36 countries in sub-Saharan Africa did not receive the full course of life-saving preventive treatment against malaria during pregnancy.
Good health starts with proper care of pregnant women and children. Protecting pregnant women, their unborn babies and newborns from malaria will improve the health of mothers and their young children in those critical first years of life and can contribute towards the achievement of Africa’s broad health and development goals,” said Her Excellency, the First Lady of the Republic of Ghana, Rebecca Akuffo-Addo.
While over 90% of lifesaving malaria intervention campaigns – including the distribution of mosquito nets and seasonal malaria chemoprevention campaigns – are on track to be completed as scheduled, malaria cases and mortality are expected to rise this year. As the COVID-19 pandemic takes its toll, millions of people, particularly pregnant women and young children, remain vulnerable to malaria because access to routine health services – such as antenatal care and malaria diagnosis and treatment is at risk of disruption as a result of COVID-19.
In response, the RBM Partnership has launched its ‘Speed Up Scale Up’ call to action, which aims to increase coverage of intermittent preventive treatment in pregnancy (IPTp) with at least three doses of a quality-assured antimalarial (sulfadoxine-pyrimethamine, or SP) to all eligible women in sub-Saharan Africa by 2025.
Governments and health officials are also urged to sustain efforts to prevent, detect, and treat malaria among pregnant women and other populations at risk so that the response to the COVID-19 pandemic does not undermine the provision of life-saving services.
“In the context of COVID-19 pandemic, it is essential that other deadly diseases such as malaria are not overlooked, or deaths will increase dramatically. Intermittent preventive therapy for pregnancy is simple and cost-effective; it saves newborn lives and prevents adverse outcomes on child development. IPTp-SP needs to be expanded substantially in all countries where it is a recommended intervention,” said Dr. Aminata Cisse ep. Traore, Deputy Director of Reproductive Health, Directorate-General of Health and Public Hygiene, Ministry of Health and Public Hygiene, Mali.
Alongside the use of insecticide-treated mosquito nets, IPTp-SP is a simple and highly cost-effective intervention recommended by the World Health Organization (WHO), which is delivered to pregnant women in Africa during antenatal care to reduce maternal anemia and the risk of low birth weight.